PUBLISHER: Grand View Research | PRODUCT CODE: 1552584
PUBLISHER: Grand View Research | PRODUCT CODE: 1552584
The global orthopedic biomaterials market size is expected to reach USD 35.90 billion by 2030, growing at a CAGR of 7.5% from 2024 to 2030, according to a new study by Grand View Research, Inc. Several key factors, including the increasing prevalence of orthopedic conditions and advancements in biomaterial technology, drive the market. Due to an aging population and active lifestyles, the rising incidence of musculoskeletal disorders, such as osteoarthritis and fractures, is significantly boosting the demand for orthopedic biomaterials. Moreover, technological innovations, such as the development of advanced composites and smart biomaterials, enhance the performance and integration of these materials in orthopedic implants and prosthetics, thereby expanding their application and effectiveness.
The increasing prevalence of musculoskeletal disorders and chronic skeletal conditions is fueling the market growth.According to the 2023 HSE Report, approximately 473,000 workers in Great Britain experienced work-related musculoskeletal disorders (MSDs), resulting in the loss of around 6.6 million working days. These disorders accounted for 27% of all work-related ill health cases. The growing focus on minimally invasive surgical techniques also contributes to market growth. Orthopedic biomaterials that support less invasive procedures, such as bioresorbable materials and improved implant coatings, are gaining traction due to their potential to reduce recovery times and complications. The increased investment in research and development, rising healthcare expenditures, and awareness about advanced orthopedic solutions further propels the market, making it a dynamic and rapidly evolving sector.
The rising prevalence of trauma cases is also driving the demand for orthopedic biomaterials. According to an article published by WHO in June 2022, road accidents kill approximately 1.3 million people worldwide, and approximately 20 to 50 million people suffer from non-fatal injuries. These injuries often require orthopedic surgery, leading to an increased demand for orthopedic biomaterials.